ClinicalTrials.Veeva
Menu

Find clinical trials for Alzheimer's Disease in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Mental Disorders
Brain Diseases
Neurodegenerative Diseases
Nervous System Diseases

Alzheimer's Disease trials near Paris, Île-de-France, FRA:

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...

Active, not recruiting
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Solanezumab
Drug: E2814

Phase 2, Phase 3

The Washington University
The Washington University

Paris, Paris, France and 37 other locations

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...

Active, not recruiting
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Lecanemab
Drug: Matching Placebo (E2814)

Phase 2, Phase 3

The Washington University
The Washington University

Paris, Paris, France and 35 other locations

This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in p...

Enrolling
Alzheimer's Disease
Biological: VHB937
Other: Placebo

Phase 2

Novartis
Novartis

Paris, France and 71 other locations

Locations recently updated

This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.

Invitation-only
Alzheimer's Disease Psychosis
Drug: ACP-204

Phase 3

Acadia Pharmaceuticals
Acadia Pharmaceuticals

Paris, France and 76 other locations

This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...

Enrolling
Alzheimer's Disease Psychosis
Drug: Placebo
Drug: ACP-204

Phase 2, Phase 3

Acadia Pharmaceuticals
Acadia Pharmaceuticals

Paris, France and 148 other locations

Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease...

Active, not recruiting
Alzheimer Disease
Mild Cognitive Impairment
Drug: NIO752
Drug: Matching placebo

Phase 1

Novartis
Novartis

Paris, France and 9 other locations

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease...

Enrolling
Alzheimer's Disease
Other: Placebo
Drug: KarXT

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Paris, France and 125 other locations

efficacy of device RGn600 in treating patients with mild-to-moderate Alzheimer's disease (AD). RGn600 is a non-invasive medical dev...

Enrolling
Alzheimer Disease
Device: RGn600
Device: RGn600 Sham
REGEnLIFE

Paris, France and 5 other locations

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab SC
Drug: Placebo

Phase 3

Eisai
Eisai

Paris, Paris, France and 246 other locations

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's...

Enrolling
Alzheimer's Disease
Drug: Placebo
Drug: Xanomeline Enteric Capsule

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Paris, France and 146 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems